Form 4 for TLSI TriSalus Life Sciences, Inc.
Accepted 2026-03-20 00:00:00 ET · period of report 2026-03-11 · accession 0001628280-26-020186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-20 | 2026-03-11+ | TLSI | Szela Mary T | CEO, Pres, Dir | S - Sale | $3.91 | -20.3K | 768.9K | -3% | -$79.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-17 | S | D | 15,944 | $3.85 | 752,987 | D | — | — | (F1) Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. |
| 2 | Common | Common Stock | 2026-03-11 | S | D | 4,358 | $4.13 | 768,931 | D | — | — | (F1) Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. |